Robert Barrow - 03 Feb 2026 Form 4 Insider Report for Definium Therapeutics, Inc. (DFTX)

Role: Chief Executive Officer, Director
Signature: /s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow
Issuer symbol: DFTX
Transactions as of: 03 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Feb 2026, 16:53:18 UTC
Previous filing: 29 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Barrow Robert	Chief Executive Officer, Director	C/O DEFINIUM THERAPEUTICS, INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK	/s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow	05 Feb 2026	0001897557

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DFTX	Common Shares	Award	$0	+320,000	+41%	$0.000000	1,098,477	03 Feb 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.